The US successfully tested the type of 'glue' in cancer treatment

US scientists have identified a lumican protein molecule that can bind chemicals that kill cells into cancer tissue, opening up the possibility of developing a low-toxicity cancer therapy.

Using the lumican as the collagen-binding lumican, more than 90% of the mice survived the cytokine injection - (Photo: MIT news).

According to Science Translational Medicine , scientists at the Massachusetts Institute of Technology have found a molecule that can bind chemicals to destroy cells into cancer tissue, opening up the possibility of developing a cancer treatment. Low-toxicity mail. In particular, this protein molecule does not allow cytokines to leave the tumor because the Velcro-like protein (Velcro-like protein) can prevent cytokines from escaping after they are injected into the tumor.

Previous studies have determined that cytokines - small proteins released by immune cells to communicate with each other, have the potential to treat cancer if combined with other immunotherapies. but they are highly toxic to both healthy tissues.

Oncologists have tried to inject cytokine directly into the tumor, but those compounds within minutes have left the tumor. In the latest study, scientists screened different proteins in the tumor. They focused their attention on collagen in solid tumors. They then attached a collagen-binding protein called lumican to the cytokines.

In the trial, 2 cytokines were introduced into tumors of malignant cancerous mice. In its pure form, the inclusion of cytokines leads to the death of all rats, and if combined with immunotherapy, only a few lives will be saved. But when using lumican as the collagen-binding lumican , more than 90% of rats survived.